Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that ...

Eli Lilly is sharpening its competitive edge in the crowded oral SERD arena as the FDA has approved a combination of its ...

Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout ...

Eli Lilly (LLY) on Friday announced that the U.S. FDA granted full approval for an all-oral regimen containing its estrogen receptor antagonist Inluriyo and kinase inhibitor Verzenio as a late-line ...

Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S.

This marks the second FDA approval for Inluriyo in less than a year, following its September 2025 approval as monotherapy for the treatment of adults with ER+, HER2-, ESR1-mutated MBC whose disease ...

Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market.

Eli Lilly is marking World Alzheimer’s Day with a partnership to distribute 13,500 boxes of brain-healthy fresh produce and ...

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

Lilly Wachowski, co-director of The Matrix trilogy, is no longer interested in being a part of groundbreaking series.

The US FDA has approved Eli Lilly's drug combination to treat adults with a type of advanced breast cancer that ​has spread to other parts of the body, the drugmaker ‌said on Friday.

The drugmaker has a lot riding on continued clinical progress.